STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1637 by analyst upside · 2026-08-13
TARS
Tarsus Pharmaceuticals, Inc.
Healthcare · Market Cap $3B · P/E 0x
ANALYST PRICE TARGET
+35.9%
implied upside to consensus target
Current Price $70.02
Consensus Target $95.14
Bull Target $104.0
Bear Target $84.0
Analysts Covering 7
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
7
Hold
0
Sell
0
52-Week Low $48.2
52-Week High $85.25
YTD Return -13.3%
FUNDAMENTALS
Market Cap $3B
P/E Ratio (TTM) N/A
Forward P/E 31.9x
EPS (TTM) $-1.08
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $606M
Profit Margin -7.7%
52-WEEK RANGE
52-Week Low $48.2
52-Week High $85.25
Current Price $70.02
Bear Target $84.0
Bull Target $104.0
● Now $70.02 ● Target $95.14
TRADING DATA
Avg Volume 971K
YTD Return -13.3%
Analyst Count 7
Consensus Buy
Upside to Target +35.9%
Last Updated 2026-08-13

ANALYST SUMMARY

Tarsus Pharmaceuticals, Inc. (TARS) is currently trading at $70.02 with a Wall Street consensus price target of $95.14, implying potential upside of 35.9% over the next 12 months. 7 analysts currently cover TARS, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $104.0, while the most cautious has a target of $84.0.

TARS operates in the Healthcare sector with a market capitalisation of $3B. The stock is down 13.3% year-to-date and is currently trading near the upper end of its 52-week range of $48.2 – $85.25.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for TARS, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HC Wainwright & Co. reit
Buy → Buy 2026-05-04 31% win rate (48 calls)
Oppenheimer - Reiterated
Outperform → Outperform 2026-02-25 14% win rate (7 calls)
Guggenheim - Reiterated
Buy → Buy 2026-02-25 62% win rate (8 calls)
Barclays ● Initiated
Overweight 2025-12-09 Building track record
Mizuho ● Initiated
Outperform 2025-11-20 Building track record
Guggenheim - Reiterated
Buy → Buy 2025-11-05 62% win rate (8 calls)
HC Wainwright & Co. - Reiterated
Buy → Buy 2025-10-20 31% win rate (48 calls)
Goldman Sachs - Reiterated
Neutral → Neutral 2025-05-05 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
67
out of 100
Coverage depth
16/30
Consensus clarity
24/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →